AR Holdings Claims Par Pharma Infringed Gout Drug Patent

Law360, New York (April 5, 2012, 3:33 PM EDT) -- Mutual Pharmaceutical Co. affiliate AR Holding Co. Inc. on Wednesday lodged a patent suit against Par Pharmaceutical Inc., alleging the drugmaker has infringed 10 of its patents covering methods for producing gout medication.

AR Holding maintains that Woodcliff Lake, N.J.-based Par has submitted an abbreviated new drug application to the Food and Drug Administration seeking to market a 0.6 mg oral tablet generic version of the brand name gout drug Colcrys, before its patent rights covering the medication expire.  

At issue are U.S. Patents No....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.